Lakshman Gunaratnam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lakshman Gunaratnam has a total of 214 co-authors. Here are the top co-authors by number of shared publications:
Ola Z. Ismail
Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, London, Ontario, Canada; Matthew Mailing Centre for Translational Transplant Studies, Lawson Health Research Institute, London, Ontario, Canada
6 shared publicationsElena Tutunea-Fatan
Matthew Mailing Centre for Translational Transplant Studies, Lawson Health Research Institute, London Health Sciences Centre, London, Ontario, Canada
5 shared publicationsXizhong Zhang
Matthew Mailing Center for Translational Transplant Studies, London Health Sciences Center Lawson Health Research Institute London Ontario Canada
5 shared publications- Abubaker. M. E. Sidahmed
Immunogenetics and Transplantation Laboratory, London Health Sciences Centre and Pathology and Laboratory Medicine University Hospital London Ontario Canada
4 shared publications Ji Yun Lee
Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, London, Ontario, Canada
4 shared publications- Rita S. Suri
Division of Nephrology, Department of Medicine, McGill University, Montreal, Québec, Canada
4 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Elsevier in Kidney International Case Reports
Chronic Parvovirus B19-associated Pure Red Cell Aplasia Following Kidney Transplantation: A Case Report
- 30 September 2026
- Published by Elsevier in Kidney International Case Reports
Open AccessChronic Parvovirus B19-associated Pure Red Cell Aplasia Following Kidney Transplantation: A Case Report
Characterisation of the HLA‐DPA1*01:194:01:02 Allele by Next‐Generation Sequencing
Novel HLA‐DPA1*01:194:01:02 allele identified in Canadian liver transplant candidate of European descent by next‐generation sequencing.
Characterisation of the HLA‐DPA1*01:194:01:02 Allele by Next‐Generation Sequencing
Novel HLA‐DPA1*01:194:01:02 allele identified in Canadian liver transplant candidate of European descent by next‐generation sequencing.
- Open Access
- 15 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1832945
Understanding the role of non-HLA antibodies in kidney transplantation: a literature review
Non-HLA antibodies have emerged as important contributors to antibody-mediated rejection and long-term graft dysfunction in kidney transplantation, including in patients without detectable donor-specific antibodies against human leukocyte antigens (HLA-DSAs). This review summarizes current evidence on major non-HLA antibody targets, including angiotensin II type 1 receptor, endothelin A receptor, perlecan fragment LG3, vimentin, major histocompatibility complex class I chain-related molecule A, collagen, fibronectin, natural antibodies, and glutathione S-transferase theta 1, and highlights their mechanisms of formation, pathogenic roles, and clinical associations. These antibodies can arise through alloimmune or autoimmune processes, often driven by endothelial injury, ischemia-reperfusion injury, and inflammatory signaling, which may expose cryptic antigens and promote loss of self-tolerance. Mechanistically, non-HLA antibodies can mediate graft injury through complement activation, Fc receptor–dependent immune responses, and direct signaling effects on endothelial and vascular cells, leading to inflammation, microvascular injury, and fibrosis. Importantly, they can act synergistically with HLA-DSA, amplifying immune responses, and contributing to worse transplant outcomes. However, findings across studies remain inconsistent due to heterogeneity in detection methods, lack of standardized thresholds for positivity, and variability in patient populations. Additionally, temporal dynamics in antibody development and fluctuations over time suggest that static measurements may not fully capture their clinical relevance. The presence of non-HLA antibodies in healthy populations further complicates interpretation and highlights the need to better define clinically meaningful thresholds. Given the wide diversity in antigen targets, biological functions, and mechanisms of action, a one-size-fits-all approach is insufficient. Instead, individual non-HLA antibodies should be investigated through targeted mechanistic and clinical studies to clarify their specific roles in transplant outcomes. Future research should prioritize large-scale, multicenter prospective studies with standardized methodologies, alongside mechanistic investigations, to improve risk stratification and advance understanding of their impact on long-term kidney transplant success.
- 15 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1832945
Open AccessUnderstanding the role of non-HLA antibodies in kidney transplantation: a literature review
Non-HLA antibodies have emerged as important contributors to antibody-mediated rejection and long-term graft dysfunction in kidney transplantation, including in patients without detectable donor-specific antibodies against human leukocyte antigens (HLA-DSAs). This review summarizes current evidence on major non-HLA antibody targets, including angiotensin II type 1 receptor, endothelin A receptor, perlecan fragment LG3, vimentin, major histocompatibility complex class I chain-related molecule A, collagen, fibronectin, natural antibodies, and glutathione S-transferase theta 1, and highlights their mechanisms of formation, pathogenic roles, and clinical associations. These antibodies can arise through alloimmune or autoimmune processes, often driven by endothelial injury, ischemia-reperfusion injury, and inflammatory signaling, which may expose cryptic antigens and promote loss of self-tolerance. Mechanistically, non-HLA antibodies can mediate graft injury through complement activation, Fc receptor–dependent immune responses, and direct signaling effects on endothelial and vascular cells, leading to inflammation, microvascular injury, and fibrosis. Importantly, they can act synergistically with HLA-DSA, amplifying immune responses, and contributing to worse transplant outcomes. However, findings across studies remain inconsistent due to heterogeneity in detection methods, lack of standardized thresholds for positivity, and variability in patient populations. Additionally, temporal dynamics in antibody development and fluctuations over time suggest that static measurements may not fully capture their clinical relevance. The presence of non-HLA antibodies in healthy populations further complicates interpretation and highlights the need to better define clinically meaningful thresholds. Given the wide diversity in antigen targets, biological functions, and mechanisms of action, a one-size-fits-all approach is insufficient. Instead, individual non-HLA antibodies should be investigated through targeted mechanistic and clinical studies to clarify their specific roles in transplant outcomes. Future research should prioritize large-scale, multicenter prospective studies with standardized methodologies, alongside mechanistic investigations, to improve risk stratification and advance understanding of their impact on long-term kidney transplant success.
The Novel HLA‐C*01:303 Allele, Identified in a Living Liver Donor of Canadian Dutch Descendent
The novel HLA‐C*01:303 allele was identified in a Canadian donor of Dutch descent by next‐generation sequencing.
The Novel HLA‐C*01:303 Allele, Identified in a Living Liver Donor of Canadian Dutch Descendent
The novel HLA‐C*01:303 allele was identified in a Canadian donor of Dutch descent by next‐generation sequencing.
The Novel DPB1*1927:01N Allele, Identified in a Potential Kidney Donor
HLA‐DPB1*1927:01N differs from HLA‐DPB1*15:01:01:01 by a single base substitution in exon 3 .
The Novel DPB1*1927:01N Allele, Identified in a Potential Kidney Donor
HLA‐DPB1*1927:01N differs from HLA‐DPB1*15:01:01:01 by a single base substitution in exon 3 .
- Open Access
- 23 June 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (7) , 378
Kidney Injury Molecule-1 (KIM-1) in Renal Cell Carcinoma: Biological Foundations and Emerging Clinical Applications
Renal cell carcinoma (RCC) is a biologically heterogeneous malignancy characterized by variable clinical behavior and diverse molecular phenotypes. Although immune checkpoint inhibitors and targeted therapies have transformed the treatment landscape of advanced RCC, clinically validated biomarkers capable of improving risk stratification, therapeutic-decision making and disease monitoring remain lacking. Kidney injury molecule-1 (KIM-1), also known as hepatitis A virus cellular receptor-1 (HAVCR1) or T-cell immunoglobulin and mucin domain-containing protein-1 (TIM-1), has emerged as a biologically compelling investigational biomarker e because of its close relationship to proximal tubular epithelial injury and renal carcinogenesis. KIM-1 is a transmembrane glycoprotein minimally expressed in normal kidney tissue but markedly upregulated in dedifferentiated proximal tubular epithelial cells following injury, and in clear cell RCC, where its extracellular domain can be shed into plasma and urine. Beyond its role as a marker of tubular injury, KIM-1 participates in immune regulation, phagocytosis, inflammatory signaling and tissue remodeling, supporting its potential relevance to tumor biology. Clinical studies have demonstrated associations between elevated circulating KIM-1 levels and RCC diagnosis, recurrence risk, and survival outcomes, particularly in localized and postoperative disease settings. KIM-1 has additionally been investigated as a therapeutic target through antibody–drug conjugate approaches. Despite promising translational data, important limitations yet remain. Current evidence is predominantly prognostic rather than predictive, and substantial analytical and biological challenges continue to limit implementation. Assay standardization, clinically meaningful cutoffs, specimen selection, timing of sampling, and confounding by chronic kidney disease or nonmalignant renal injury remain incompletely resolved. Furthermore, evidence supporting incremental value beyond established clinicopathologic models remains limited. This review critically evaluates the biological rationale, analytical considerations and clinical evidence supporting KIM-1 in RCC. Particular emphasis is placed on distinguishing prognostic, predictive, pharmacodynamic, and therapeutic applications, as well as defining the evidentiary gaps that must be addressed before clinical implementation. Current evidence is derived predominantly from retrospective and exploratory analyses, and important limitations remain regarding assay standardization, biological specificity, chronic kidney disease-related confounding, and prospective validation. The review concludes with a summary of the evolving landscape of KIM-1-directed biomarker strategies in RCC, which may ultimately contribute to improved biologic risk stratification and biomarker-driven clinical investigation in RCC.
- 23 June 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (7) , 378
Open AccessKidney Injury Molecule-1 (KIM-1) in Renal Cell Carcinoma: Biological Foundations and Emerging Clinical Applications
Renal cell carcinoma (RCC) is a biologically heterogeneous malignancy characterized by variable clinical behavior and diverse molecular phenotypes. Although immune checkpoint inhibitors and targeted therapies have transformed the treatment landscape of advanced RCC, clinically validated biomarkers capable of improving risk stratification, therapeutic-decision making and disease monitoring remain lacking. Kidney injury molecule-1 (KIM-1), also known as hepatitis A virus cellular receptor-1 (HAVCR1) or T-cell immunoglobulin and mucin domain-containing protein-1 (TIM-1), has emerged as a biologically compelling investigational biomarker e because of its close relationship to proximal tubular epithelial injury and renal carcinogenesis. KIM-1 is a transmembrane glycoprotein minimally expressed in normal kidney tissue but markedly upregulated in dedifferentiated proximal tubular epithelial cells following injury, and in clear cell RCC, where its extracellular domain can be shed into plasma and urine. Beyond its role as a marker of tubular injury, KIM-1 participates in immune regulation, phagocytosis, inflammatory signaling and tissue remodeling, supporting its potential relevance to tumor biology. Clinical studies have demonstrated associations between elevated circulating KIM-1 levels and RCC diagnosis, recurrence risk, and survival outcomes, particularly in localized and postoperative disease settings. KIM-1 has additionally been investigated as a therapeutic target through antibody–drug conjugate approaches. Despite promising translational data, important limitations yet remain. Current evidence is predominantly prognostic rather than predictive, and substantial analytical and biological challenges continue to limit implementation. Assay standardization, clinically meaningful cutoffs, specimen selection, timing of sampling, and confounding by chronic kidney disease or nonmalignant renal injury remain incompletely resolved. Furthermore, evidence supporting incremental value beyond established clinicopathologic models remains limited. This review critically evaluates the biological rationale, analytical considerations and clinical evidence supporting KIM-1 in RCC. Particular emphasis is placed on distinguishing prognostic, predictive, pharmacodynamic, and therapeutic applications, as well as defining the evidentiary gaps that must be addressed before clinical implementation. Current evidence is derived predominantly from retrospective and exploratory analyses, and important limitations remain regarding assay standardization, biological specificity, chronic kidney disease-related confounding, and prospective validation. The review concludes with a summary of the evolving landscape of KIM-1-directed biomarker strategies in RCC, which may ultimately contribute to improved biologic risk stratification and biomarker-driven clinical investigation in RCC.
- Open Access
- 29 April 2026
- Published by MDPI AG in Preprints.org
Kidney Injury Molecule-1 (KIM-1) in Renal Cell Carcinoma: Bridging Tumor Biology and Clinical Decision-Making
Renal cell carcinoma (RCC) remains a biologically heterogeneous disease with variable clinical outcomes, underscoring the need for robust biomarkers to guide risk stratification and therapeutic decision-making. Despite advances in immune checkpoint inhibitors and targeted therapies, clinically validated biomarkers are lacking, particularly in the perioperative setting. Kidney injury molecule-1 (KIM-1; also known as HAVCR1 or TIM-1) has emerged as a promising candidate with strong biological and clinical rationale. KIM-1 is a transmembrane glycoprotein minimally expressed in normal kidney tissue but markedly upregulated in injured and dedifferentiated proximal tubular epithelial cells, the cell of origin for clear cell RCC. Its extracellular domain is shed into circulation and urine, enabling non-invasive quantification. Beyond its role as a marker of renal injury, KIM-1 is implicated in immune modulation, chronic inflammation, and tumor biology, supporting its role as a dynamic indicator of tumor burden and disease aggressiveness. This review presents the current evidence supporting KIM-1 as a circulating biomarker and therapeutic target in RCC and discusses emerging strategies to address disease heterogeneity through biomarker-driven approaches. We examine its biological role, clinical utility in early detection and postoperative risk stratification, integration with other emerging biomarkers, and its development as a target for antibody–drug conjugates. The review concludes with a summary of the evolving landscape of KIM-1–directed biomarker strategies in RCC, which hold promise to refine patient selection, improve risk-adapted management, and advance precision oncology in this complex disease.
- 29 April 2026
- Published by MDPI AG in Preprints.org
Open AccessKidney Injury Molecule-1 (KIM-1) in Renal Cell Carcinoma: Bridging Tumor Biology and Clinical Decision-Making
Renal cell carcinoma (RCC) remains a biologically heterogeneous disease with variable clinical outcomes, underscoring the need for robust biomarkers to guide risk stratification and therapeutic decision-making. Despite advances in immune checkpoint inhibitors and targeted therapies, clinically validated biomarkers are lacking, particularly in the perioperative setting. Kidney injury molecule-1 (KIM-1; also known as HAVCR1 or TIM-1) has emerged as a promising candidate with strong biological and clinical rationale. KIM-1 is a transmembrane glycoprotein minimally expressed in normal kidney tissue but markedly upregulated in injured and dedifferentiated proximal tubular epithelial cells, the cell of origin for clear cell RCC. Its extracellular domain is shed into circulation and urine, enabling non-invasive quantification. Beyond its role as a marker of renal injury, KIM-1 is implicated in immune modulation, chronic inflammation, and tumor biology, supporting its role as a dynamic indicator of tumor burden and disease aggressiveness. This review presents the current evidence supporting KIM-1 as a circulating biomarker and therapeutic target in RCC and discusses emerging strategies to address disease heterogeneity through biomarker-driven approaches. We examine its biological role, clinical utility in early detection and postoperative risk stratification, integration with other emerging biomarkers, and its development as a target for antibody–drug conjugates. The review concludes with a summary of the evolving landscape of KIM-1–directed biomarker strategies in RCC, which hold promise to refine patient selection, improve risk-adapted management, and advance precision oncology in this complex disease.
- Top Cited PapersOpen Access
- 26 March 2026
- Published by Elsevier in Kidney International
- Vol. 110 (1) , 190-205
Genetic testing in kidney transplantation and living kidney donor risk assessment
- 26 March 2026
- Published by Elsevier in Kidney International
- Vol. 110 (1) , 190-205
Top Cited PapersOpen AccessGenetic testing in kidney transplantation and living kidney donor risk assessment
- 17 March 2026
- Published by Wolters Kluwer Health in Transplantation
- Vol. 110 (6) , e1340-e1342
Valve Replacement With Decellularized Homografts may Impede Solid Organ Transplantation
- 17 March 2026
- Published by Wolters Kluwer Health in Transplantation
- Vol. 110 (6) , e1340-e1342
Valve Replacement With Decellularized Homografts may Impede Solid Organ Transplantation
- Open Access
- 13 February 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (5) , 962-979
Adenosine deaminase acting on RNA 1 and receptor-interacting serine/threonine-protein kinase-1 orchestrate the Z-DNA-binding protein 1–mediated PANoptosis and mouse heart transplant rejection
- 13 February 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (5) , 962-979
Open AccessAdenosine deaminase acting on RNA 1 and receptor-interacting serine/threonine-protein kinase-1 orchestrate the Z-DNA-binding protein 1–mediated PANoptosis and mouse heart transplant rejection